PF-07832837 for Eczema

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Pfizer

Must not be taking: Antibiotics, Antivirals, Antifungals, others

Disqualifiers: Infections, Malignancies, Skin diseases, others

Trial Summary

What is the purpose of this trial?The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are taking medications for other inflammatory skin diseases or have had recent skin infections, you may need to discuss this with the trial team.

Eligibility Criteria

This trial is for healthy adults aged 18-55 (Part 1) and those with moderate to severe atopic dermatitis aged 18-70 (Part 2), who have a BMI of 17.5 to 40 kg/m2 and weigh over 50 kg. Participants should either not respond well to topical treatments or cannot use them due to side effects.

Inclusion Criteria

My BMI is between 17.5 and 40, and I weigh more than 110 lbs.

I am between 18 and 55 years old and can consent to participate.

I am generally healthy as confirmed by a recent medical check-up.

+6 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment - Single Ascending Dose (SAD)

Participants receive single ascending doses of PF-07832837 or placebo to evaluate safety, tolerability, and pharmacokinetics

5 weeks

Multiple visits (in-person)

Treatment - Multiple Ascending Dose (MAD)

Participants receive multiple ascending doses of PF-07832837 or placebo to evaluate safety, tolerability, and pharmacokinetics

7 weeks

Multiple visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Participant Groups

The study tests PF-07832837, a new medication, against a placebo in both healthy participants and those with atopic dermatitis. It aims to assess the drug's safety, how it's processed by the body, dosage levels, and its effect on skin condition symptoms.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: PF-07832837Experimental Treatment1 Intervention

single or multiple doses of PF-07832837 at ascending dose levels

Group II: placeboPlacebo Group1 Intervention

single or multiple doses of placebo